KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Capital Expenditures (2017 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Capital Expenditures for 18 consecutive years, with $21.8 million as the latest value for Q1 2026.

  • For Q1 2026, Capital Expenditures rose 498.16% year-over-year to $21.8 million; the TTM value through Mar 2026 reached $29.1 million, up 679.34%, while the annual FY2025 figure was $10.9 million, 369.1% up from the prior year.
  • Capital Expenditures hit $21.8 million in Q1 2026 for Alnylam Pharmaceuticals, up from -$24.5 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $31.3 million in Q3 2025 and bottomed at -$43.1 million in Q4 2023.
  • Average Capital Expenditures over 5 years is $2.6 million, with a median of $1.6 million recorded in 2024.
  • Year-over-year, Capital Expenditures crashed 4470.2% in 2023 and then soared 9858.26% in 2025.
  • Alnylam Pharmaceuticals' Capital Expenditures stood at -$943000.0 in 2022, then plummeted by 4470.2% to -$43.1 million in 2023, then soared by 103.67% to $1.6 million in 2024, then crashed by 1648.86% to -$24.5 million in 2025, then soared by 189.1% to $21.8 million in 2026.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $21.8 million, -$24.5 million, and $31.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.